托珠单抗治疗重症COVID-19肺炎的前瞻性随机双盲安慰剂对照试验(TOC-COVID)方案结构化摘要
TOC-COVID是一项多中心、前瞻性、随机双盲安慰剂对照试验,旨在评估单次静脉注射托珠单抗治疗重症COVID-19肺炎的疗效与安全性。主要终点为随机后28天内无呼吸机天数,计划入组200例,随机前已注册。
要点
- 托珠单抗8mg/kg单次静脉给药,对照组为安慰剂加常规治疗。
- 主要终点为28天内无呼吸机天数,死亡计为零。
- 需密切监测免疫抑制可能增加的细菌感染风险。
核心结论
- 研究假设托珠单抗可减缓SARS-CoV-2诱导的肺炎和炎症进展,改善肺功能,减少机械通气依赖天数和呼吸支持侵入性,并可能减少ICU入住。
研究设计与样本
- 多中心、前瞻性、2臂随机(1:1)、双盲、安慰剂对照、平行组试验,在德国10个医疗中心招募住院患者。
- 计划随机入组每组100例,共200例;随机按中心分层,区组长度可变且不披露。
- 主要随访为随机后28天(住院期间收集数据),随后在6和12个月进行电话生活质量访谈。
关键数值与推荐
- 干预组:随机后立即单次静脉注射托珠单抗8mg/kg体重(体重<30kg者12mg/kg;总剂量不超过800mg)加常规治疗;对照组:安慰剂(生理盐水)静脉注射加常规治疗。
- 主要终点:随机后28天内无呼吸机天数(VFD);无创通气、有创机械通气和ECMO均定义为呼吸机天数;28天内死亡者VFD计为零。
- 入选标准:SARS-CoV2证据(症状和PCR阳性);严重呼吸衰竭(环境空气SpO2≤92%或需≥6L O2/min或NIV或IMV);年龄≥18岁。
- 排除标准包括:NIV或IMV≥48小时、妊娠或哺乳、肝损伤或衰竭(AST/ALT≥5倍ULN)、白细胞<2×10^3/μl、血小板<50×10^3/μl、严重细菌感染(PCT>3ng/ml)等。
- 试验注册:EudraCT No. 2020-001408-41(2020年4月21日注册)和DRKS No. DRKS00021238(2020年4月22日注册)。
临床怎么用
- 对于重症COVID-19肺炎患者,可考虑单次托珠单抗8mg/kg静脉给药,但需严格筛选符合入选标准且无排除标准的患者。
- 治疗期间应密切监测细菌感染等免疫抑制相关不良事件。
局限性
- 本摘要为研究方案的结构化总结,未报告实际试验结果。
- 样本量有限(计划200例),可能影响亚组分析效能。
- 试验在德国10个中心进行,外部推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Objective of this study is to evaluate the efficacy and safety of a single dose treatment with Tocilizumab in patients with severe COVID-19. We hypothesize that Tocilizumab slows down the progression of SARS-CoV-2 induced pneumonia and inflammation. We expect an improvement in pulmonary function compared to placebo-treated patients. Desirable outcomes would be that tocilizumab reduces the number of days that patients are dependent on mechanical ventilation and reduces the invasiveness of breathing assistance. Furthermore, this treatment might result in fewer admissions to intensive care units. Next to these efficacy parameters, safety of a therapy with Tocilizumab in COVID-19 patients has to be monitored closely, since immunosuppression could lead to an increased rate of bacterial infections, which could negatively influence the patient's outcome. TRIAL DESIGN: Multicentre, prospective, 2-arm randomised (ratio 1:1), double blind, placebo-controlled trial with parallel group design. PARTICIPANTS: Inclusion criteria 1.Proof of SARS-CoV2 (Symptoms and positive polymerase chain reaction (PCR))2.Severe respiratory failure: a.Ambient air SpO2 ≤ 92% orb.Need of ≥ 6l O2/min orc.NIV (non-invasive ventilation) ord.IMV (invasive mechanical ventilation)3.Age ≥ 18 years Exclusion criteria 1.Non-invasive or invasive mechanical ventilation ≥ 48 hours2.Pregnancy or breast feeding3.Liver injury or failure (AST/ALT ≥ 5x ULN)4.Leukocytes < 2 × 103/μl5.Thrombocytes < 50 × 103/μl6.Severe bacterial infection (PCT > 3ng/ml)7.Acute or chronic diverticulitis8.Immunosuppressive therapy (e.g. mycophenolate, azathioprine, methotrexate, biologicals, prednisolone >10mg/d; exceptions are: prednisolone ≤ 10mg/d, sulfasalazine or hydroxychloroquine)9.Known active or chronic tuberculosis10.Known active or chronic viral hepatitis11.Known allergic reactions to tocilizumab or its ingredients12.Life expectation of less than 1 year (independent of COVID-19)13.Participation in any other interventional clinical trial within the last 30 days before the start of this trial14.Simultaneous participation in other interventional trials (except for participation in COVID-19 trials) which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed15.Failure to use one of the following safe methods of contraception: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception. The data collection of the primary follow up (28 days after randomisation) takes place during the hospital stay. Subsequently, a telephone interview on the quality of life is conducted after 6 and 12 months. Participants will be recruited from inpatients at ten medical centres in Germany. INTERVENTION AND COMPARATOR: Intervention arm: Application of 8mg/kg body weight (BW) Tocilizumab i.v. once immediately after randomisation (12 mg/kg for patients with <30kg BW; total dose should not exceed 800 mg) AND conventional treatment. Control arm: Placebo (NaCl) i.v. once immediately after randomisation AND conventional treatment. MAIN OUTCOMES: Primary endpoint is the number of ventilator free days (d) (VFD) in the first 28 days after randomisation. Non-invasive ventilation (NIV), Invasive mechanical ventilation (IMV) and extracorporeal membrane oxygenation (ECMO) are defined as ventilator days. VFD's are counted as zero if the patient dies within the first 28 days. RANDOMISATION: The randomisation code will be generated by the CTU (Clinical Trials Unit, ZKS Freiburg) using the following procedure to ensure that treatment assignment is unbiased and concealed from patients and investigator staff. Randomisation will be stratified by centre and will be performed in blocks of variable length in a ratio of 1:1 within each centre. The block lengths will be documented separately and will not be disclosed to the investigators. The randomisation code will be produced by validated programs based on the Statistical Analysis System (SAS). BLINDING (MASKING): Participants, caregivers, and the study team assessing the outcomes are blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 100 participants will be randomised to each group (thus 200 participants in total). TRIAL STATUS: Protocol Version: V 1.2, 16.04.2020. Recruitment began 27th April 2020 and is anticipated to be completed by December 2020. TRIAL REGISTRATION: The trial was registered before trial start in trial registries (EudraCT: No. 2020-001408-41, registered 21st April 2020, and DRKS: No. DRKS00021238, registered 22nd April 2020). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Rilinger J, Kern WV, Duerschmied D, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32493514. doi:10.1186/s13063-020-04447-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。